Actively Recruiting
Rifampin in CYP24A1-related Hypercalcemia and Hypercalciuria
Led by Children's Hospital of Philadelphia · Updated on 2025-07-28
60
Participants Needed
1
Research Sites
644 weeks
Total Duration
On this page
Sponsors
C
Children's Hospital of Philadelphia
Lead Sponsor
N
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study evaluates the efficacy of rifampin in the treatment of hypercalcemia and/or hypercalciuria in participants with at least one inactivating mutation of the CYP24A1 gene. Eligible subjects will receive rifampin for a total of 16 weeks during this study.
CONDITIONS
Official Title
Rifampin in CYP24A1-related Hypercalcemia and Hypercalciuria
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Males or females age 6 months to 65 years
- At least one mutation of CYP24A1
- Serum and/or urinary calcium above the normal reference range for age
- Serum parathyroid hormone concentration less than 20 pg/ml
- Elevated or normal serum concentration of 1,25-dihydroxyvitamin D3
You will not qualify if you...
- Parents, guardians, or subjects likely to be non-compliant with study schedules or procedures
- Allergy to rifampin or related medications
- Current use of medications that significantly interact with rifampin by affecting CYP3A4 or CYP3A5 enzyme function
- Pregnancy or breastfeeding
- Laboratory abnormalities indicating significant liver or kidney disease including:
- Aspartate Aminotransferase (AST/SGOT) more than 2 times the upper limit of normal
- Alanine aminotransferase (ALT/SGPT) more than 2 times the upper limit of normal
- Total bilirubin more than 2 times the upper limit of normal
- Creatinine more than 2 times the upper limit of normal
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States, 19104
Actively Recruiting
Research Team
M
Michael A Levine, MD
CONTACT
V
Vashisht Arshanapally
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here